Results 151 to 160 of about 65,592 (243)

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, Volume 158, Issue 9, Page 2440-2451, 1 May 2026.
What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Complete Response to Nivolumab-Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First-Line Nivolumab-Ipilimumab: A Case Report. [PDF]

Cancer Rep (Hoboken)
Patel R, Post-Zwicker L, Kaur V.
europepmc   +1 more source

A Case of Fulminant Immune‐Related Enterocolitis During Immune Checkpoint Inhibitor Therapy for Metastatic Renal Cell Carcinoma

IJU Case Reports, Volume 9, Issue 3, May 2026.
ABSTRACT Introduction Combination therapy with immune checkpoint inhibitors (ICIs) has become a standard treatment for metastatic renal cell carcinoma (mRCC). However, ICIs may also cause immune‐related adverse events. We report a case of mRCC that developed fulminant immune‐related enterocolitis.
Kasumi Kanai, Takayuki Sumiyoshi, Hiroki Kitamoto, Yuki Teramoto, Yuta Mine, Jin Kono, Kimihiko Masui, Takayuki Goto, Ryoichi Saito, Takashi Kobayashi   +9 more
wiley   +1 more source

Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report. [PDF]

Oncologist
AlSharif H, Danchine V, Deekollu K, Hasanov M, Wu R, Haykal T, Faieta A, Verschraegen CF.   +7 more
europepmc   +1 more source

Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies

MedComm, Volume 7, Issue 5, May 2026.
The mechanism of multiple signaling pathways and their related targeted inhibitors in HCC. (A) The mechanism of Ras/Raf/MEK/ERK signaling pathway and its related targeted inhibitors; (B) the mechanism of PI3K/AKT/mTOR signaling pathway and its crosstalk with other pathways and its related targeted inhibitors; (C) the mechanism of JAK/STAT signaling ...
Penghui He, Sinan Xie, Kunlin Xie, Fengwei Gao, Yunshi Cai, Yan Huang, Chang Liu, Hong Wu, Yinghao Lyu, Tian Lan   +9 more
wiley   +1 more source

Perioperative immunotherapy for advanced resectable melanoma: a cost-effectiveness analysis. [PDF]

BMC Health Serv Res
Rui M, Wei Q, Wang Y, You JHS.
europepmc   +1 more source

Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors

Otolaryngology–Head and Neck Surgery, Volume 174, Issue 5, Page 1289-1297, May 2026.
Abstract Objective Hearing loss from immune checkpoint inhibitors (ICIs) has been documented in case reports and case series. We present the largest retrospective study investigating the rate of ICI‐related ototoxicity in a monitored cohort of platinum‐naïve patients. Study Design Retrospective cohort study. Setting Tertiary‐care center.
Kaitlyn A. Brooks, Christopher G. Gidley, Olivia Grimley, Catherine Wang, Shirin Jivani, Dianna Roberts, Aung Naing, Jack Phan, Katherine Hutcheson, Xin Wang, Paul W. Gidley, Marc‐Elie Nader   +11 more
wiley   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. [PDF]

Cancer
Luo J, Li Z, Ge J, Cai S, Mo X, Liu W, Gui C, Du Q, Liu J.   +8 more
europepmc   +1 more source

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. [PDF]

J Clin Oncol
Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, Bautista Aragon Y, Talbot T, Grossi F, Kowalski D, Kaplan MA, Cardona AF, Soomro R, Hu N, Lee A, Ip V, Hung YH, Zalcman G.   +19 more
europepmc   +1 more source